Pharming (PHAR) Long-Term Deferred Tax (2019 - 2026)

Pharming (PHAR) has 8 years of Long-Term Deferred Tax data on file, last reported at $28.8 million in Q2 2026.

• Quarterly Long-Term Deferred Tax fell 7.57% year-over-year to $28.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $28.8 million (down 7.57% YoY) and the FY2025 annual result came in at $31.0 million, up 1.55% from the prior year.
• Long-Term Deferred Tax slipped to $28.8 million in Q2 2026, from $30.7 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $39.0 million in Q2 2024 to a low of $21187.0 in Q3 2022.
• A 5-year average of $26.9 million and a median of $29.1 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax slumped 99.9% — and 2023, when it soared 125486.44%.
• Tracing PHAR's Long-Term Deferred Tax over 5 years: stood at $23.0 million in 2022, then climbed by 29.55% to $29.8 million in 2023, then increased by 2.63% to $30.5 million in 2024, then increased by 1.55% to $31.0 million in 2025, then retreated by 7.03% to $28.8 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $28.8 million (Q2 2026), $30.7 million (Q1 2026), and $31.0 million (Q4 2025), per Business Quant data.